Founded in July 2016 and headquartered in Brooklyn, New York, Concarlo is a precision-medicine oncology company focused on diagnosing and treating cancer with an innovative approach to targeting a unique cellular pathway - p27Kip1.
Concarlo's novel IpY therapeutic will be the first inhibitor to solve the CDK2 resistance issue, the first therapeutic to target p27 and the first to inhibit CDK4 and CDK2 simulataneously.
Industry
Biotechnology Research, Scientific Research and Development Services, Services
HQ Location
760 Parkside Ave
Brooklyn, New York 11226, US
Keywords
BiotechDrug developmentCancer ResearchBreast CancerDrug-resistant Breast Cancerp27Kip1molecular pharmacologybiomedical engineeringoncology drugdrug delivery technology